Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly EBT Margin of 1277.02% for Q1 2026, up 25623.0% year-over-year from N/an in Q1 2025, and down 218.51% quarter-over-quarter from 400.94% in Q4 2025.
Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported EBT Margin for 12 consecutive years, with 1277.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 25623.0% year-over-year to 1277.02%; the TTM figure through Mar 2026 stood at 945.8% (up 51888.0% YoY), while the FY2025 annual figure was 1960.12%, up 23361.0% from the prior year.
- EBT Margin declined to 1277.02% in Q1 2026 per NTLA's latest filing, from 400.94% in the prior quarter.
- Across five years, EBT Margin topped out at 8521.39% in Q4 2023 and bottomed at 4122.35% in Q4 2022.
- Historically, EBT Margin has averaged 969.91% across 5 years, with a median of 1385.28% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 1447721 bps — and 2024, when it plunged 950139 bps.
- Intellia Therapeutics' EBT Margin stood at 4122.35% in 2022, then jumped by 307 bps to 8521.39% in 2023, then tumbled by 112 bps to 980.01% in 2024, then surged by 59 bps to 400.94% in 2025, then plunged by 219 bps to 1277.02% in 2026.
- Business Quant data shows NTLA's EBT Margin at 1277.02% in Q1 2026, 400.94% in Q4 2025, and 1613.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -2,530.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,530.19% |
| Mar 31, 2026 | -1,277.02% |
| Dec 31, 2025 | -400.94% |
| Sep 30, 2025 | -1,613.80% |
| Jun 30, 2025 | -829.98% |
| Mar 31, 2025 | -1,533.25% |
| Dec 31, 2024 | -980.01% |
| Sep 30, 2024 | -1,579.39% |
| Jun 30, 2024 | -2,047.45% |
| Mar 31, 2024 | -445.81% |
| Dec 31, 2023 | 8,521.39% |
| Sep 30, 2023 | -1,319.11% |
| Jun 30, 2023 | -1,385.28% |
| Mar 31, 2023 | -1,264.14% |
| Dec 31, 2022 | -4,122.35% |
| Sep 30, 2022 | -1,662.81% |
| Jun 30, 2022 | -1,450.67% |
| Mar 31, 2022 | -3,097.89% |
| Dec 31, 2021 | -2,992.79% |
| Sep 30, 2021 | -9,349.96% |